Difference between revisions of "Carboplatin (Paraplatin)"
Jump to navigation
Jump to search
m |
m (→References) |
||
Line 178: | Line 178: | ||
[[Category:Drugs FDA approved in 1989]] | [[Category:Drugs FDA approved in 1989]] | ||
+ | [[Category:WHO Essential Cancer Medicine]] |
Revision as of 18:31, 5 June 2016
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bladder cancer
- Bone cancer
- Breast cancer
- Central nervous system (CNS) cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Extranodal NK/T-cell lymphoma, nasal type
- Head and neck cancer
- Hodgkin lymphoma
- Melanoma
- Mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Prostate cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Uterine cancer
- Unknown primary
Patient drug information
- Carboplatin (Paraplatin) patient drug information (Chemocare)[4]
- Carboplatin (Paraplatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 3/3/1989: Initial FDA approval
Also known as
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Abic Carboplatin | Biocarb | Biocarbo | Bioplatinex | Biovinate | Blastocarb | Blastocarb RU | BO BEI |
Bonaplatin | Boplatex | Carbo | Carbo-Cell | Carbokem | Carbomedac | Carbomerck | Carbomerck Merk Hoei |
Carboplat | Carboplatin-GRY | Carboplatin-Teva | Carboplatin Abic | Carboplatin D-W | Carboplatin DBL | Carboplatine | Carboplatine eurocept |
Carboplatine Aguettant | Carboplatin Ebewe | Carboplatine Dakot | Carboplatine Dakota | Carboplatine Eurocept | Carboplatine G GAM | Carboplatine Mayne Pharma (BEN) | Carboplatine Merck |
Carboplatine Teva | Carboplatin Hexal | Carboplatin Lens | Carboplatin Mayne | Carboplatino | Carboplatino Delta | Carboplatino Ferrer | Carboplatino Ferrer Farma |
Carboplatino Filaxis | Carboplatino Martian | Carboplatino MAY | Carboplatino Microsules | Carboplatino Montedison | Carboplatino Pharmacia | Carboplatino PHU | Carboplatino Raffo |
Carboplatino Rontag | Carboplatino Teva | Carboplatin Sanofi-Synthelabo | Carboplatinum | Carbosin | Carbotanil | Carbotec | Carbotinol |
Careptin | Carplan | Carplanil | Carpsol | cis-Diammine(1 | 1-cyclobutanedicarboxylato)platinum(II) | Crobextin | Cycloplatin |
Cycloplatinum | Emorzim | Erbakar | Ercar | Fauldcarbo | Ifacap | Kemocarb | Mega Carboplatin |
Megaplatin | Nealorin | Neocarb | Neocarbo | Oncocarb | Oncocarbin AQ | P&U Carboplatin | Paraplatin AQ |
Paraplatine | Paraplatin RTU | Pharmaplatin | Platamine CS | Platinwas | Ribocarbo | Ribocarbo-L | Tecnocarb |
Trav Carboplatin | Vancel |
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Platinum agents
- Alkylating agents
- Irritant chemotherapy
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Cancer of unknown primary medications
- Central nervous system (CNS) cancer medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Head and neck cancer medications
- Hodgkin lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Prostate cancer medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Testicular cancer medications
- Thymoma medications
- Uterine cancer medications
- Drugs FDA approved in 1989
- WHO Essential Cancer Medicine